Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Friday, November 07, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Ganga Pharmaceuticals approved unaudited financial results for the half year ended September 30, 2025. Revenue from operations stood at ₹136.65 lakhs, up modestly from ₹131.13 lakhs in the same period last year (about 4% growth). However, total income fell to ₹151.45 lakhs from ₹160.42 lakhs because other income dropped sharply to ₹14.80 lakhs from ₹29.29 lakhs. Net profit was very thin at ₹2.48 lakhs, with basic EPS of ₹0.04. Auditor Banka & Banka issued a clean limited review report with no qualifications. The company also allotted 10.75 lakh equity shares on conversion of warrants, raising ₹112.88 lakhs and increasing paid-up capital to ₹591.15 lakhs.
Results indicate weak operating performance with negligible bottom-line profit despite revenue growth, and warrant conversion has diluted existing shareholders; however, fresh capital of ~₹113 lakhs provides modest liquidity support for this small-cap pharma company.